F03625 – Cardiovascular Trial
Fusion Clinical Research Norwood
Adults aged 18 years or older may be eligible for a clinical trial evaluating an investigational cardiovascular treatment aimed at reducing major adverse cardiovascular events in people who have elevated Lipoprotein(a).
Never had your levels of Lipoprotein(a) tested?
Don’t worry, we will check this for you as part of the eligibility assessment.
The study includes 19-20 visits over a period of about 4 years.
Participants receive compensation for their time.
Sign up below to see if this study is right for you.
Eligibility requirements
- Age: 18+
- Sex: M & F
- Medication: Participants taking statins or prescription-strength niacin must be on a stable dose for at least 4 weeks prior to trial. Participants taking cholesterol lowering PCSK9 inhibitors (such as Alirocumab (Praluent), Evolocumab (Repatha), or Inclisiran (Leqvio)) must be on a stable dose for at least 8 weeks prior to trial.
- Medical History: Eligibility requirements (not limited to): Adults aged 18 years or older, in good health or with stable medical conditions. Lp(a) levels ≥175 nmol/L at screening or pre-screening (we will measure this for you). History of Atherosclerotic Cardiovascular Disease or at risk for a first Atherosclerotic Cardiovascular Disease event. If you have Atherosclerotic Cardiovascular Disease, the most recent event must not have occurred within 90 days prior to screening. Cannot have uncontrolled blood pressure or severe heart failure. Cannot have severe kidney impairment. Cannot be pregnant, breast-feeding or plan to become pregnant or breast-feed during the study.
Overnight Stays
- Nil
Outpatient Visits
- 19-20 visits
Payment/Remuneration
- Participants are compensated for their time of $75 per site visit and $48 for meals in the event the visit requires fasting.
How to apply
To register your interest in this trial, please complete the form below, or call us on 1800-FUSION (1800 387 466). A Fusion team member will be in contact to discuss your eligibility shortly.